CVS Specialty

Accordant: Holistic Support for Patients with Complex Conditions

Bottom of the article
10.29.19
A photo of a doctor putting hand on patient’s shoulder.

Managing rare or complex conditions can often be challenging for patients. They can feel overwhelmed by the condition, medication side effects, complex dosage instructions, comorbidities, complicated provider directions, and experience challenges trying to navigate the health care system.

Health plans and employers, can adopt and offer our Accordant program for their plan members. Accordant provides holistic support for patients with rare conditions through targeted interventions designed to meet each patient’s unique needs.

The specialized care team is composed of registered nurses, pharmacists, social workers, and a medical director – all backed by a medical advisory board. These skilled practitioners set mutually agreed-upon health goals with the patient, discuss symptom management, explain proper use of medications, and even deal with resource issues such as lack of transportation to doctors’ appointments or cost of care. In addition, social workers help patients with community resources such as negotiating utility bill payments, identifying support groups, and grants for home modifications.

In a recent Blue Cross Blue Shield blog post, Accordant Medical Director Dr. Andrew Krueger discusses the importance of comprehensive care management services for patients with complex conditions such as multiple sclerosis and the difference this kind of care can make.

A photo showing a doctor putting hand on patient’s shoulder.
Hide Media Contacts (Sidebar)
No
Article
Hide Share
Off
"Likes" Count
0

Improving the Infusion Therapy Experience with Coram

Bottom of the article
09.26.19

As health care costs continue to rise, payers, providers and patients are looking for new ways to help improve quality of patient care and their experience while lowering overall costs. One promising area is in home infusion care.

In fact, published research has shown that the home infusion services, like those provided by Coram CVS Specialty Services, can be safe and beneficial for those patients requiring infused therapies and in some cases can be a lower cost alternative to receiving the same services in a hospital or inpatient setting. In addition, the research has also shown that patients overwhelmingly prefer receiving their infusion therapies at home.

Read more about the benefits and value of home infusion care from Tricia Lacavich, Vice President for CVS Specialty Coram Infusion Services, in her recent article in Fierce Healthcare.

A patient and a caregiver sitting on a sofa.
Hide Media Contacts (Sidebar)
No
Article
Hide Share
Off
"Likes" Count
0

Streamlining Prescription Onboarding with Specialty Expedite

Bottom of the article
09.25.19

As CVS Health looks to transform health care and contribute to a better, more efficient system, we are looking at ways to leverage and improve the use of technology to improve quality of care and patient outcomes.

This is especially important in specialty pharmacy and why we’ve introduced Specialty Expedite.Specialty Expedite is available exclusively for providers who use compatible electronic health record (EHR) systems including Epic Systems and others that participate in the Carequality Interoperability Framework. All data sharing and usage complies with applicable privacy laws. Patients receive real-time prescription status updates only after providing consent to CVS Specialty. Our connected capability transforms prescription onboarding for our CVS Specialty patients, on average shortening the specialty pharmacy onboarding process to as little as three days and ultimately helping to get patients started on appropriate therapy faster.

Getting Patients the Medications They Need Quickly and Efficiently

For patients with complex medical conditions requiring specialty medications, getting started on their prescriptions quickly and efficiently is crucial to their care. But the process has not always been that simple, with patients sometimes having to wait as long as several weeks to complete the manual onboarding and prior authorization process.

Specifically, the process to get started on a specialty medication often requires physician’s offices and insurers to fax appropriate patient records and/or required approvals before a prescription can be filled, which can be time consuming but is a critical step to ensure that patients are receiving the most appropriate medication.

In addition, across the health care system, the Federal government is looking at ways to help enable and improve health information technology (IT) systems and as part of that, officials have even called for health care to be a “fax free zone by 2020.”

How It Works

Specialty Expedite works by securely gathering appropriate patient information, including insurance, lab work and diagnosis codes via a doctor’s electronic health record (EHR) system instead of sharing through fax. The process also cuts down on paperwork and phone calls, resulting in fewer errors and more efficiencies.

In addition, patients also now have the option of receiving real-time status updates via email or text, so that they can stay informed on the status of their prescriptions and any prior authorization requirements. Patients are also able to choose how they want to get their specialty medications — at their local CVS Pharmacy or though specialty mail serviceWhere allowed by law. In-store pick up is currently not available in Oklahoma. Puerto Rico requires first-fill prescriptions to be transmitted directly to the dispensing specialty pharmacy. Products are dispensed by CVS Specialty and certain services are only accessed by calling CVS Specialty directly. Certain specialty medication may not qualify. Services are also available at Long’s Drugs locations. via Specialty Connect. Research shows that when patients have more flexibility and choice, they are able to start their therapies sooner and adherence and satisfaction improves.

Helping patients with complex medical conditions get the specialty medication they need more quickly and efficiently through technology and solutions such as Specialty Expedite is one more way we are helping people on their path to better health.

For more information about CVS Health’s efforts to improve care across the nation, visit our News & Insights page and the CVS Health Impact Dashboard. To stay informed about the latest updates and innovations from CVS Health, register for content alerts and our Leaders in Care newsletter.

A photo of a smiling pharmacist at computer.
Hide Media Contacts (Sidebar)
No
Article
Hide Share
Off
"Likes" Count
1

Supporting Our Patients with Chronic Disease

Supporting Our Patients with Chronic Disease
Bottom of the article
09.19.19
A doctor comforting a female patient.

As we transform the health care experience for all patients, we pay special attention to the needs of patients with chronic diseases who seek care more frequently. We continue to invest in the development of smart and robust solutions to address the health impacts and escalating costs related to chronic disease in the U.S. Our efforts include expanding preventive care and treatment for chronic conditions, improving medication adherence, coordinating care across the healthcare system, engaging patients where they are, and offering healthier product options at our stores.

Personalizing Care Solutions

Our Transform Care programs continue to deliver frequent and highly personalized care to millions of CVS Caremark members who are managing a chronic condition. The programs combine patient-related health and pharmacy data with drug cost management strategies that make care more effective, affordable and easy to navigate.

Transform Diabetes Care, introduced in 2016, has since been adopted by more than 230 CVS Caremark clients, representing 3.4 million members. The program uses advanced analytics to identify members with diabetes and target appropriate interventions. A certified coach develops and helps execute personalized management plans for Type 2 diabetes patients based on their pharmacy data and electronic health record information. The patients use at-home, connected glucometers for glucose readings, which their coach can monitor to offer help as needed. The program also ensures patients receive prescription refill reminders, in-person counseling on diabetes management, and comprehensive diabetes visits at MinuteClinic locations at no out-of-pocket cost.

By 2021, we plan to offer an enhanced diabetes program that combines CVS Health’s local and pharmacy care with Aetna’s care management, targeting, analytics and other capabilities, resulting in a best-in-class diabetes and chronic offering. The enhanced program will derive from the current Transform Diabetes Care model, making for a seamless transition and member experience for clients who wish to adopt the enhanced product. Features of the enhanced product may include:

Aetna’s care managers can provide a single point of contact for members with chronic conditions regardless of which conditions members have. The member’s care manager will also have access to the member’s information from their engagement in the Transform Diabetes Care program and can coach based off of that information.

Creating Comprehensive Programs for Complex Conditions

Another way we are reducing costs and enhancing patient care is through the development of comprehensive programming designed specifically for complex chronic conditions like kidney disease and cancer.

In 2018, we introduced a program to support patients with End Stage Renal Disease (ESRD), a disease that affects nearly 700,000 Americans. Taking a staged approach, our program seeks to slow the progression of ESRD and reduce associated hospitalizations. Beginning with early disease identification and patient education, the program will follow with the development of a comprehensive home dialysis program, for both hemodialysis and peritoneal dialysis. Understanding that longer, more frequent hemodialysis treatments often lead to better outcomes, we will initiate a pivotal clinical trial of a new home hemodialysis device in support of a planned U.S. Food and Drug Administration (FDA) submission to obtain market clearance.

We will select new program participants by determining who is most at risk for kidney disease and progression to kidney failure, as identified through medical and pharmacy claims data and predictive analytics algorithms, in accordance with HIPAA. Our Accordant Care nurses will engage these individuals to educate them on their risk level, important tests they should consider taking, and the need to see a nephrologist. This team will work with individuals as they progress toward ESRD.

We also work with our health care partners and clients to help manage the cost of oncology care while ensuring access to vital therapies for patients. Our approach promotes evidence-based cancer care, lower-cost but clinically equivalent treatment options, and a holistic patient care model that helps patients adhere to therapy. An important component of our cancer care approach is helping providers stay up-to-date with the latest research and advancements, a challenge in the fast-paced field of oncology.

In 2018, we partnered with the leading oncology organization National Comprehensive Cancer Network (NCCN) to provide physicians with a tool to access the latest evidence-supported information. Treatment Guidelines from the NCCN are integrated into Novologix, CVS Health’s proprietary technology platform, and serve as the clinical foundation of multi-drug regimen prior authorization (PA) for physicians and patients. Novologix helps drive cost-effective regimen selection by determining treatment coverage that meets treatment plan needs.

To learn about the many other ways we’re supporting our chronic disease patients, read our 2018 Corporate Social Responsibility Report.

To stay up-to-date on the latest CVS Health Social Responsibility news and content, sign up for email news alerts.

A doctor comforting a female patient.
Hide Media Contacts (Sidebar)
No
Article
Hide Share
Off
"Likes" Count
0

Clinical Secure Messaging Helps Improve Medication Adherence

Clinical Secure Messaging Helps Improve Medication Adherence
Bottom of the article
04.03.19
Graph showing Medication adherence improved in both groups of patients who used secure messaging.
Medication adherence improved in both groups of patients who used secure messaging.
Graph showing more optimal medication adherence with secure messaging.
Optimal medication adherence improved for both groups of patients using secure messaging.
Graph showing a decrease in the first-fill drop-off rate for patients using secure messaging.
First-fill drop-off rate also decreased among patients using secure messaging.

Historically, people with complex conditions may receive telephonic or in-person support from a specially trained nurse or pharmacist with the goal of helping the patient better manage their condition(s), take their medication(s) as prescribed and improve their overall health outcomes. In this increasingly digital age, however, people are turning to technology for help with a range of things, including health care.

Recognizing this shift toward digital engagement, CVS Specialty is bringing patients innovative digital and online tools to help them better manage their conditions and access additional support online. This includes secure, two-way messaging that puts a nurse or pharmacist at the patients’ fingertips.

Powering this capability is a proprietary, company-built tool loaded with therapy- and indication-specific clinical information. Patients opt-in to receive personalized message alerts via their mobile phone asking if they are experiencing certain common medication side effects. The messages are based on clinical trial data, the drug’s label and feedback from other patients, and are timed to reach the patient when they are more likely to experience a specific side effect. The message also includes a link to enable the patient to ask the pharmacist a medication-related question.

Following the launch of this tool for patients with chronic myeloid leukemia (CML), initial results were promising, with high engagement rates and improved medication adherence, compared to more traditional support methods, including telephonic outreach.

Scaling to Other Specialty Conditions

With positive results in patients with CML, CVS Specialty quickly expanded use of this tool across all specialty conditions and recently conducted a retrospective analysis of specialty pharmacy claims and use of secure messaging in patients with rheumatoid arthritis (RA) and multiple sclerosis (MS).

These findings were recently presented at the Academy of Managed Care Pharmacy annual meeting and showed that patients with these complex conditions can also benefit from this type of digital support when compared to more traditional support methods. Specifically, patients who received the customized, secure clinical messages on topics including adherence, condition management or side effect management, every 30 days, were more likely to re-fill their prescription(s) and achieved significantly higher medication adherence than the control group. In fact, optimal adherence for patients in the study with either MS or RA receiving this digital clinical support improved by 3.82% and 2.12% points, respectively.

At CVS Specialty, the goal is to help patients on their path to better health by offering support where and when patients need it most. This data shows the promise of clinical support delivered digitally and, as part of a health care innovation company, CVS Specialty is committed to continuing to help more patients manage their diseases in a way that meets their individual needs.

Hide Media Contacts (Sidebar)
No
Article
Hide Share
Off
"Likes" Count
0

CVS Health and Omnicare Sign Definitive Agreement for CVS Health to Acquire Omnicare

Top of the article
05.21.15

WOONSOCKET, R.I.and CINCINNATI, May 21, 2015 /PRNewswire/ -- CVS Health Corporation (NYSE:CVS) and Omnicare, Inc. (NYSE:OCR) announced today that they have entered into a definitive agreement for CVS Health to acquire Omnicare, the leading provider of pharmacy services to long term care facilities, for $98.00 per share in cash, for a total enterprise value of approximately $12.7 billion, which includes approximately $2.3 billion in debt. In total, Omnicare has approximately 13,000 employees at 160 locations in 47 states across the U.S.

With the acquisition of Omnicare, CVS Health will significantly expand its ability to dispense prescriptions in assisted living and long term care facilities, serving the senior patient population. CVS Health will also expand its presence in the rapidly growing specialty pharmacy business. Omnicare's complementary specialty pharmacy platform and clinical expertise will augment CVS Health's capabilities and enable CVS Health to continue to provide innovative and cost-effective solutions to patients and payors.

The boards of directors of both companies have approved the transaction, which is subject to approval by the holders of Omnicare's common stock, as well as other customary closing conditions, including applicable regulatory approvals. The transaction is expected to close near the end of 2015.

CVS Health expects to achieve significant purchasing and revenue synergies as well as operating efficiencies from this combination. The company expects the transaction to be approximately 20 cents accretive to Adjusted EPS in 2016, its first full year, excluding integration and any one-time transaction costs. It is expected to become increasingly accretive to Adjusted EPS in subsequent years. The company has secured $13 billion in fully committed unsecured bridge financing from Barclays and expects to put in place permanent financing in the form of senior notes and/or term loans prior to the closing of the transaction. CVS Health expects that it will continue to have a solid balance sheet and, with its strong free cash flow, is committed to returning to its targeted leverage ratio of 2.7 times adjusted debt-to-EBITDA.

"The acquisition of Omnicare significantly expands our business, providing CVS Health access into a new pharmacy dispensing channel," said CVS Health President and CEO Larry Merlo. "It also creates new opportunities for us to extend our high-quality, innovative pharmacy programs to a broader population of seniors and chronic care patients as they transition across the care continuum. We have been impressed by the Omnicare team and what they have created for the patients they serve."

"We are pleased to have reached this agreement with CVS Health, one of the leading companies in the health care industry, which we believe will allow us to accelerate our mission of enhancing the quality and cost-effectiveness of care for complex patient populations," said Omnicare President and CEO Nitin Sahney. "This exciting combination is the result of a broad and thorough review of our strategic options. On behalf of the Omnicare team, I'd like to thank our 13,000 employees whose hard work and dedication has enabled Omnicare to become a recognized leader in pharmacy services."

Given the aging U.S. population, long term care is a growth segment of the health care system. More people are expected to use assisted living facilities and independent living communities in the coming decades, creating a substantial growth opportunity for those companies serving the health care needs of seniors.

In entering this new customer distribution channel, CVS Health will deliver meaningful benefits to consumers, patients, caregivers, and payors by providing highly coordinated clinical pharmacy care across multiple treatment settings from retail to long term care. CVS Health will help improve patient outcomes and provide enhanced continuity of care to patients and caregivers as they transition through the health care system.

CVS Health received investment banking and financial advice from Barclays and Evercore. The company was advised on transaction legal matters by Sullivan & Cromwell LLP and on antitrust matters by Dechert LLP.

BofA Merrill Lynch and Centerview Partners are serving as financial advisors to Omnicare. White & Case LLP is serving as Omnicare's legal counsel.

Teleconference and Webcast

CVS Health will be holding a conference call today for the investment community at 8:30 am (EDT) to discuss the transaction. The dial-in number for the call is 800-750-5849 or, for international callers, 212-231-2921. An audio webcast of the call will be broadcast simultaneously on CVS Health's website for all interested parties. To access the webcast, please visit the investor relations section of the company's website at http://investors.cvshealth.com/. A replay of the call will be available from approximately 10:30 am (EDT) on May 21 through 10:30 am (EDT) on May 28. It can be accessed by dialing 800-633-8284 or, for international callers, 402-977-9140, and entering access code 21769309. The webcast will be archived and available on the CVS Health website for a one-year period following the conference call.

About CVS Health
CVS Health (NYSE: CVS) is a pharmacy innovation company helping people on their path to better health. Through its 7,800 retail drugstores, nearly 1,000 walk-in medical clinics, a leading pharmacy benefits manager with more than 70 million plan members, and expanding specialty pharmacy services, the Company enables people, businesses and communities to manage health in more affordable, effective ways. This unique integrated model increases access to quality care, delivers better health outcomes and lowers overall health care costs. Find more information about how CVS Health is shaping the future of health at www.cvshealth.com.

About Omnicare
Omnicare, Inc., a Fortune 500 company based in Cincinnati, Ohio, provides comprehensive pharmaceutical services to patients and providers across the United States. As the market-leader in professional pharmacy, related consulting and data management services for skilled nursing, assisted living and other chronic care institutions, Omnicare leverages its unparalleled clinical insight into the geriatric market along with some of the industry's most innovative technological capabilities to the benefit of its long-term care customers. Omnicare also provides specialty pharmacy and key commercialization services for the bio-pharmaceutical industry through its Specialty Care Group. For more information, visit www.omnicare.com.

Cautionary Statement Regarding Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws. By their nature, all forward-looking statements involve risks and uncertainties. Actual results may differ materially from those contemplated by the forward-looking statements for a number of reasons as described in our Securities and Exchange Commission filings, including those set forth in the Risk Factors section and under the section entitled "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. The factors that could cause actual results to differ materially include the following: the possibility that the anticipated synergies and other benefits from the proposed acquisition of Omnicare by CVS Health will not be realized, or will not be realized within the expected time periods; the inability to obtain regulatory approvals of the proposed acquisition (including the approval of antitrust authorities necessary to complete the transaction) on the terms desired or anticipated; the timing of such approvals and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the transaction; the risk that a condition to closing the transaction may not be satisfied on a timely basis or at all; the risk that the proposed transaction fails to close for any other reason; the risks and uncertainties related to CVS Health's ability to successfully integrate the operations, products and employees of Omnicare; the effect of the potential disruption of management's attention from ongoing business operations due to the pending acquisition; the effect of the announcement of the proposed transaction on CVS Health's and Omnicare's relationships with their respective customers, vendors and lenders and on their respective operating results and businesses generally; access to available financing on a timely basis and on reasonable terms; the outcome of any legal proceedings related to the proposed acquisition; and the risks and uncertainties normally incidental to the respective businesses of CVS Health and Omnicare. Additional information concerning these and other risks and uncertainties can be found in CVS Health's and Omnicare's periodic reports filed with the U.S. Securities and Exchange Commission (the "SEC"). Copies of these filings, as well as subsequent filings, are available online at www.sec.gov, www.cvshealth.com, www.omnicare.com or on request from CVS Health or Omnicare, as applicable. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as otherwise required by law, neither CVS Health nor Omnicare undertakes any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Additional Information and Where to Find It
This communication may be deemed to be solicitation material in respect of the proposed acquisition of Omnicare, Inc. by CVS Pharmacy, Inc., a wholly owned subsidiary of CVS Health Corporation. In connection with the proposed acquisition, CVS Health and Omnicare intend to file relevant materials with the SEC, including Omnicare's proxy statement on Schedule 14A. INVESTORS AND STOCKHOLDERS OF OMNICARE ARE ADVISED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING OMNICARE'S PROXY STATEMENT WHEN IT BECOMES AVAILABLE BEFORE MAKING ANY VOTING OR INVESTMENT DECISIONS WITH RESPECT TO THE PROPOSED ACQUISITION BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain the proxy statement (when available) and other relevant documents free of charge at the SEC's web site, http://www.sec.gov, and Omnicare stockholders will receive information at an appropriate time on how to obtain transaction-related documents for free from Omnicare.

Participants in Solicitation
CVS Health and its directors and executive officers, and Omnicare and its directors and executive officers, may be deemed to be participants in the solicitation of proxies from the holders of Omnicare common stock in connection with the proposed acquisition. Information about the directors and executive officers of CVS Health is set forth in the proxy statement for CVS Health's 2015 Annual Meeting of Stockholders, which was filed with the SEC on March 27, 2015. Information about the directors and executive officers of Omnicare is set forth in the proxy statement for Omnicare's 2015 Annual Meeting of Stockholders, which was filed with the SEC on April 17, 2015. Additional information regarding potential participants in such proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be included in the proxy statement and other relevant materials filed by Omnicare with the SEC in connection with the proposed acquisition when they become available.

Contacts:

For CVS Health:
Nancy Christal
Senior Vice President
Investor Relations
(914) 722-4704

Carolyn Castel
Vice President
Corporate Communications
(401) 770-5717
Carolyn.Castel@CVSHealth.com

For Omnicare:
Patrick Lee
Senior Vice President
Investor Relations
(513) 719-1507
patrick.lee@omnicare.com

Logo- http://photos.prnewswire.com/prnh/20140905/143585

SOURCE CVS Health Corporation

Press Release
"Likes" Count
0

CVS Health Expands National Partnership with Arthritis Foundation to Become the Exclusive Specialty Pharmacy 'Partner for Better Living'(SM)

Top of the article
10.09.15

WOONSOCKET, R.I., Oct. 9, 2015 /PRNewswire/ -- CVS Health (NYSE: CVS) announced today, in advance of World Arthritis Day on October 12, the expansion of a national partnership with the Arthritis Foundation to help advance arthritis advocacy, research and patient support. As part of the partnership, CVS/specialty, the specialty pharmacy of CVS Health, will be designated an Arthritis Foundation 'Partner for Better Living'(SM) and be its first and only specialty pharmacy partner. The distinction recognizes CVS/specialty's commitment to helping people with arthritis and joint pain, and builds on the longstanding relationship between the two organizations. CVS/pharmacy is currently the exclusive retail drugstore partner of the Arthritis Foundation.

"Our expanded partnership with the Arthritis Foundation will allow us to extend our purpose of helping people on their path to better health by supporting an organization dedicated to advancing education, access to care, advancements in science and community connections for people with arthritis," said Alan Lotvin, MD, executive vice president of specialty pharmacy for CVS/caremark, the pharmacy benefits manager of CVS Health. "CVS/specialty is a different kind of pharmacy with services that offer convenience, care and support for our patients with complex conditions, like rheumatoid arthritis, so they have the freedom to focus on every part of their lives, not just their condition."

As an Arthritis Foundation 'Partner for Better Living,' CVS/specialty is helping people with certain forms of arthritis take control of managing their complex condition by supporting them with specialized tools, personalized care and convenient access to medications. In fact, the unique model of CVS/specialty is focused on making it easier for patients with a range of complex conditions to start and stay on their prescriptions.

"We're pleased to expand the important work we're doing with CVS Health as the Arthritis Foundation continues to help people living with arthritis conquer every day battles," said Ann M. Palmer, president and chief executive officer of the Arthritis Foundation."We know that access to information and treatment is crucial for people living with arthritis, and with CVS/specialty as a 'Partner for Better Living,' we are now able to better support the millions of Americans with arthritis, including the 1.5 million with rheumatoid arthritis requiring specialty medicines."

CVS/specialty offers the support of a Care Team comprised of pharmacists and nurses who specialize in chronic conditions such as rheumatoid arthritis and insurance specialists who work to find assistance for those with a financial hardship. Patients also have access to personalized specialty infusion care conveniently provided in the home or at an alternative infusion suite. In addition, CVS/specialty simplifies getting started on therapy by offering patients the choice of pickup at their local CVS/pharmacy, or delivery to their home, office or other location. Patients have access to online tools and a free mobile app where they can order refills, track deliveries and get reminders to help them stay on track. For more information about CVS/specialty, visit www.cvsspecialty.com

Since 2014, CVS/pharmacy has been an Arthritis Foundation 'Partner for Better Living' and a one-stop-shop for arthritis-related products, services and resources in-store and online. As part of the partnership, many CVS/pharmacy locations across the country house the Arthritis Solutions Center, which features products and resources to help better support people living with arthritis. By expandingthe national partnership with the Arthritis Foundation, CVS Health can better support the full spectrum of people living with arthritis and joint pain.

About CVS Health
CVS Health (NYSE: CVS) is a pharmacy innovation company helping people on their path to better health. Through its more than 7,800 retail drugstores, nearly 1,000 walk-in medical clinics, a leading pharmacy benefits manager with more than 70 million plan members, and expanding specialty pharmacy services, the Company enables people, businesses and communities to manage health in more affordable, effective ways. This unique integrated model increases access to quality care, delivers better health outcomes and lowers overall health care costs. Find more information about how CVS Health is shaping the future of health at www.cvshealth.com.

About Arthritis Foundation
The Arthritis Foundation is the Champion of Yes. Leading the fight for the arthritis community, the Foundation helps conquer everyday battles through life-changing information and resources, access to optimal care, advancements in science and community connections. The Arthritis Foundation's goal is to chart a winning course, guiding families in developing personalized plans for living a full life and making each day another stride towards a cure. The Foundation also publishesArthritis Today,the award-winning magazine that reaches 4million readers.

Media Contact:

Christina Beckerman
CVS Health
(401) 770-8868
christina.beckerman@cvshealth.com

Mary Alfieri
CVS Health
401-770-9811
mary.alfieri@cvshealth.com

CVS/specialty and Arthritis Foundation(SM), Partner for Better Living(SM) logo

Logo- http://photos.prnewswire.com/prnh/20140905/143585
Logo - http://photos.prnewswire.com/prnh/20151009/275691LOGO

SOURCE CVS Health

Press Release
"Likes" Count
0

CVS Health Research Institute Study Shows 11.4 Percentage Point Improvement in Medication Adherence Among Patients in Specialty Connect™ Pilot

Top of the article
01.29.16

High cost of specialty drugs makes adherence to therapy more important than ever

WOONSOCKET, R.I., (January 29, 2016) — New research published by the CVS Health (NYSE: CVS) Research Institute showed a significant improvement in adherence to specialty medications for patients enrolled in a pilot study evaluating Specialty Connect™, CVS Health’s innovative specialty prescription services program. New patients enrolled in the pilot were 17.5 percent more likely to pickup their first refill and existing specialty patients had an 11.4 percentage point improvement in adherence, as compared to a control group. The study was published in the most recent issue of the Journal of the American Pharmacists Association.

“The specialty market is growing rapidly and new high-cost specialty drugs, that were once limited to small patient populations, are now increasingly being indicated to treat many more patients,” said William Shrank, M.D., chief scientific officer and senior vice president, CVS Health. “As new specialty medications are introduced, adherence to therapy will be particularly important to optimize the benefit of these very expensive medications. Specialty Connect, combined with evidence-based benefit design and utilization management strategies, can increase the likelihood that the most appropriate patients receive specialty medications and that, once received, they take them as prescribed.”

CVS Health piloted the Specialty Connect program in 115 CVS Pharmacy stores before launching the program nationwide. Patients enrolled in the pilot could choose to have medications delivered to their home or doctor’s office or opt to pick up their specialty medications at their local CVS Pharmacy, while receiving specialized clinical support from CVS Specialty, the specialty pharmacy of CVS Health. Since the program’s launch, more than 100,000 patients have been served, with more than half choosing to pick up their specialty prescriptions at retail.

Specialty medicines treat complex conditions such as rheumatoid arthritis, multiple sclerosis and hepatitis C. Many of these medications require special handling, storage and administration. In addition, many specialty drugs are only available at select specialty pharmacies to help ensure compliance with required safety and compliance protocols. As a result, patients often have difficulty with the logistics of filling a new prescription for a specialty medication, with as many as one quarter of traditional retail pharmacies unable to fill a specialty prescription without barriers and/or delays. CVS Specialty is the only specialty pharmacy that offers patients a choice of where to get their medicines, either at any CVS Pharmacy location or through mail delivery, which simplifies getting started on a specialty therapy. In addition, the Specialty Care Team provides round-the-clock support and patient care, including symptom management, claims processing and help managing comorbid conditions.

“CVS Specialty is the only specialty pharmacy that integrates rare disease management and coordinated care programs to make it easier for patients to start and stay on complex treatments,” added Alan Lotvin, M.D., president, CVS Specialty and executive vice president, CVS Health. “Since we launched Specialty Connect across all CVS Pharmacy locations, we have seen high rates of adherence, and our specialty patients have reported extremely high satisfaction with their service.”

The CVS Health Research Institute is focused on contributing to the body of scientific knowledge related to pharmacy and health care through research collaborations with external academic institutions, participation in federally-funded research, analysis and sharing of CVS Health data sources and coordination of pilot programs and initiatives. CVS Health Research Institute findings support a continuous quality improvement environment, which encourages product innovation and development to benefit CVS Health patients, clients and their members.

About CVS Health

CVS Health is a pharmacy innovation company helping people on their path to better health. Through its more than 9,500 retail pharmacies, more than 1,100 walk-in medical clinics, a leading pharmacy benefits manager with more than 70 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, and expanding specialty pharmacy services, the Company enables people, businesses and communities to manage health in more affordable, effective ways. This unique integrated model increases access to quality care, delivers better health outcomes and lowers overall health care costs. Find more information about how CVS Health is shaping the future of health at https://www.cvshealth.com.

Media Contacts

Christine Cramer
CVS Health
(401) 770-3317
christine.cramer@cvscaremark.com

Christina Beckerman
CVS Health
(401) 770-8868
christina.beckerman@cvscaremark.com

Hide Media Contacts (Sidebar)
No
Press Release
Hide Share
Off
"Likes" Count
0

CVS Health Statement Regarding Direct and Indirect Remuneration (DIR)

Top of the article
02.02.17

WOONSOCKET, R.I. (February 2, 2017) – CVS Health (NYSE: CVS) today released the following statement regarding Direct and Indirect Remuneration.

The Direct and Indirect Remuneration (DIR) pay-for-performance network program is an important component of the Medicare Part D program created by CMS to help beneficiaries receive higher quality care at a lower cost. It ensures optimal pharmacy performance by driving better clinical performance. Performance network fees being charged to pharmacies are allowed under CMS regulation, and are fully disclosed as part of the annual bid process. CVS Health is not profiting from this program; a change in DIR pay-for-performance networks would not be material to our profitability.

DIR pay-for-performance network fees paid by pharmacies are directly passed to Medicare Part D plan sponsors and are used to lower beneficiary premiums. These fees apply to all participating network pharmacies, including CVS Pharmacy and CVS Specialty. Under Medicare Part D, DIR is fully disclosed to CMS and factored into CMS’s calculation of final Medicare payments to Part D plans. In fact, the DIR reports expressly recognize a plan sponsor’s ability to make retroactive pharmacy payment adjustments based on performance in the DIR reporting.

Congress and CMS over the last 10+ years have incorporated pay-for-performance methodologies into Medicare fee-for-service payment systems. Additionally, Medicare Advantage (MA) plans have pay-for-performance components. Part D plans have mirrored these types of pay-for-performance methodologies, which drive clinical and network performance, because the plans pay the pharmacies directly.

CVS Heath’s profitability would not be materially affected by a change in DIR pay-for- performance networks. If the DIR construct was removed unilaterally, which we view as highly unlikely given Congress and CMS’s movement toward value-based care, all Part D plans would be impacted in the same way. Furthermore, we believe that would lead to higher premiums for beneficiaries across the industry. Congress is supportive of pay-for-performance programs and this is an important tool for the Medicare Part D program to provide higher quality care for beneficiaries at a lower cost.

About CVS Health

CVS Health is a pharmacy innovation company helping people on their path to better health.

Through its more than 9,600 retail pharmacies, more than 1,100 walk-in medical clinics, a leading pharmacy benefits manager with more than 80 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, and expanding specialty pharmacy services, the Company enables people, businesses and communities to manage health in more affordable and effective ways. This unique integrated model increases access to quality care, delivers better health outcomes and lowers overall health care costs.

Find more information about how CVS Health is shaping the future of health at https://www.cvshealth.com.

Investor Contact:

Nancy Christal
(914) 722-4704
Nancy.Christal@CVSHealth.com

Media Contact:

Carolyn Castel
(401) 770-5717
Carolyn.Castel@CVSHealth.com

Hide Media Contacts (Sidebar)
No
Press Release
"Likes" Count
0

CVS Health PBM Clients Achieved Lowest Prescription Drug Trend in Four Years, Despite Rising Drug Prices

Top of the article
03.15.17

CVS Caremark's PBM management solutions helped reduce drug trend from 5.0 percent in 2015 to just 3.2 percent in 2016

Member out-of-pocket costs dropped 3.0 percent

WOONSOCKET, R.I., March 15, 2017 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced that, in 2016, its pharmacy benefit management (PBM) clients achieved the lowest drug trend in the past four years, despite rising drug prices. CVS Caremark clients saw their prescription drug trend drop to an average of 3.2 percent compared to 5.0 percent in 2015. In addition, 38 percent of CVS Caremark commercial clients achieved a negative trend which means they actually spent less on their prescription benefit in 2016 than they did in 2015, despite rising drug prices. Out-of-pocket costs for members also dropped 3.0 percent compared to the previous year.

"No one is more concerned about the high cost of prescription drugs than CVS Health," said Troyen Brennan, M.D., Executive Vice President and Chief Medical Officer, CVS Health. "Our very favorable drug trend results for 2016 demonstrate that we have been able to deliver best-in-class value to clients and their members."

Unmanaged drug trend for 2016 was 11.0 percent, driven primarily by price inflation for branded specialty and traditional drugs, as well as increased utilization due to an aging population. CVS Caremark was able to reduce trend for clients by 7.8 percentage points to 3.2 percent through PBM management solutions that include price protection and the negotiation of rebates, of which more than 90 percent are passed back to clients. CVS Caremark also encouraged the use of less expensive generic drugs through managed formularies and applied targeted approaches to addressing high-spend drivers such as hyper-inflating drugs. On average, clients who selected the CVS Caremark standard managed formulary achieved a trend of 2.2 percent, which was less than half the trend of 4.5 percent for clients who used a custom formulary and opted out of drug removals. Additionally, clients who chose our generic-focused value formulary had the highest generic dispensing rate (GDR) at 88.2 percent and the lowest baseline cost at $81.86 per member per month.

Although overall drug price inflation was lower in 2016, it still accounted for almost 80 percent of the unmanaged trend. The relative impact of inflation on specialty branded products continued to increase relative to traditional branded medications. At the same time, overall specialty products grew to nearly 36 percent of overall gross spend. Three of the top five categories contributing to gross trend were specialty drug categories, including anti-inflammatory medications for rheumatoid arthritis and psoriasis; antineoplastics and adjunctive therapies used to treat cancer; and psychotherapeutic and neurological agents, including multiple sclerosis therapies. Meanwhile, generic utilization growth kept costs low for members as well as clients and drove a 3.5 point overall cost reduction for clients.

CVS Caremark offers a variety of solutions, including flexible formulary options based on clinical evidence, to help manage pharmacy costs while ensuring patients have access to the medications they need. In addition, CVS Caremark's strategic assessment of the pharmaceutical marketplace enables the company to negotiate aggressive rebates and help to lower costs for clients. More than 90 percent of brand manufacturer contracts also include price protection, a critical element in protecting clients in a market characterized by significant drug price increases.

Prescription drug trend is the measure of growth in prescription spending per member per month. Trend calculations take into account the effects of drug price, drug utilization and the mix of branded versus generic drugs as well as the positive effect of negotiated rebates on overall trend. The 2016 trend performance is based on a cohort of CVS Health PBM commercial clients employers and health plans.

To learn more about the CVS Caremark 2016 drug trend, click here.

About CVS Health

CVS Health is a pharmacy innovation company helping people on their path to better health. Through its more than 9,700 retail locations, more than 1,100 walk-in medical clinics, a leading pharmacy benefits manager with nearly 90 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, expanding specialty pharmacy services, and a leading stand-alone Medicare Part D prescription drug plan, the company enables people, businesses and communities to manage health in more affordable and effective ways. This unique integrated model increases access to quality care, delivers better health outcomes and lowers overall health care costs. Find more information about how CVS Health is shaping the future of health at https://www.cvshealth.com.

Media Contact

Christine Cramer
CVS Health
(401) 770-3317
christine.cramer@cvshealth.com

Investor Contact

Nancy Christal
CVS Health
(914) 722-4704
nancy.christal@cvshealth.com

SOURCE CVS Health

Hide Media Contacts (Sidebar)
No
Press Release
"Likes" Count
0